Search
RO-7293583
go.drugbank.com/drugs/DB17455InvestigationalRO-7293583 is a TYRP1-Targeting CD3 T-Cell Engager.
Phosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.
Zebularine
go.drugbank.com/drugs/DB03068ExperimentalAlso shown to inhibit DNA methylation and tumor growth both in vitro and in vivo. … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates.
Synonyms: Pyrimidin-2-one ribonucleoside, pyrimidin-2-one beta-ribofuranosideCyclopropane
go.drugbank.com/drugs/DB13984ExperimentalCyclopropane was initially investigated because it was thought to be the toxic element in ethylene. … Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.
Tovecimig
go.drugbank.com/drugs/DB30220InvestigationalNOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalIfosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Perifosine
go.drugbank.com/drugs/DB06641InvestigationalPerifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.
1-benzylimidazole
go.drugbank.com/drugs/DB04581Experimental1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.
ARCT-810
go.drugbank.com/drugs/DB17683InvestigationalARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.
EB05
go.drugbank.com/drugs/DB16477InvestigationalEB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.